First Regular Session Seventieth General Assembly STATE OF COLORADO

REENGROSSED

This Version Includes All Amendments Adopted in the House of Introduction

LLS NO. 15-0786.01 Kristen Forrestal x4217

HOUSE BILL 15-1214

HOUSE SPONSORSHIP

Singer,

SENATE SPONSORSHIP

Cooke,

House Committees

Senate Committees

Public Health Care & Human Services

A BILL FOR AN ACT

101 CONCERNING OPIOID ANALGESICS WITH ABUSE-DETERRENT 102 PROPERTIES.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at http://www.leg.state.co.us/billsummaries.)

The bill prohibits an opioid analgesic drug product that is not abuse-deterrent to be substituted for an abuse-deterrent opioid analgesic drug product if a health care provider prescribes an abuse-deterrent opioid analgesic drug product to a patient and the prescription includes the instructions "dispense as written". A carrier must cover the abuse-deterrent opioid analgesic drug product at the lowest cost-sharing Reading Unamended March 16, 2015

level as an opioid analgesic drug product. A carrier cannot require treatment failure with an opioid analgesic drug product that is not abuse-deterrent prior to providing coverage for the abuse-deterrent opioid analgesic drug product if the prescribing health care provider determines that the covered person would benefit from the abuse-deterrent opioid analgesic drug product.

1	Be it enacted by the General Assembly of the State of Colorado:
2	SECTION 1. In Colorado Revised Statutes, add 10-16-124.7 as
3	follows:
4	10-16-124.7. Opioid analgesics with abuse-deterrent properties
5	- study - definitions. (1) The governor shall direct the Colorado
6	CONSORTIUM FOR PRESCRIPTION DRUG ABUSE PREVENTION TO STUDY THE
7	BARRIERS TO AND THE EFFICACY OF THE USE OF ABUSE-DETERRENT OPIOID
8	ANALGESIC DRUG PRODUCTS AS A WAY TO REDUCE ABUSE AND DIVERSION
9	OF OPIOID DRUG PRODUCTS. ON OR BEFORE JANUARY 15, 2016, THE
10	CONSORTIUM SHALL REPORT ITS FINDINGS TO THE PUBLIC HEALTH CARE
11	AND HUMAN SERVICES COMMITTEE AND THE HEALTH, INSURANCE, AND
12	ENVIRONMENT COMMITTEE OF THE HOUSE OF REPRESENTATIVES AND THE
13	HEALTH AND HUMAN SERVICES COMMITTEE OF THE SENATE, OR THEIR
14	SUCCESSOR COMMITTEES.
15	(2) As used in this section:
16	(a) "Abuse-deterrent opioid analgesic drug product"
17	MEANS A BRAND OR GENERIC OPIOID ANALGESIC DRUG PRODUCT
18	APPROVED BY THE UNITED STATE FOOD AND DRUG ADMINISTRATION
19	WITH ABUSE-DETERRENCE LABELING CLAIMS THAT INDICATE THAT THE
20	DRUG PRODUCT IS EXPECTED TO RESULT IN A MEANINGFUL REDUCTION IN
21	ABUSE.
22	

-2-

1	(b) "OPIOID ANALGESIC DRUG PRODUCT" MEANS A DRUG PRODUCT
2	IN THE OPIOID ANALGESIC DRUG CLASS PRESCRIBED TO TREAT MODERATE
3	TO SEVERE PAIN OR OTHER CONDITIONS, WHETHER IN IMMEDIATE RELEASE
1	OR EXTENDED RELEASE OR LONG-ACTING FORM, THAT MAY BE COMBINED
5	WITH OTHER DRUG SUBSTANCES TO FORM A SINGLE DRUG PRODUCT OR
5	DOSAGE FORM.
7	SECTION 2. Safety clause. The general assembly hereby finds,
3	determines, and declares that this act is necessary for the immediate
)	preservation of the public peace, health, and safety.

-3-